



Seven Group Holdings Limited 2022 AGM Report

ASX code	SVW
Meeting date	17 November 2022
Type of meeting	Physical with webcast
Monitor	Ian Graves
Pre AGM-meeting	Yes, with Chairman Terry Davis, Gitangali Bahli Chief People Officer, Warren Coatsworth, Company Secretary

Meeting Statistics

Number of holdings represented by ASA	45
Number of shares represented by ASA	116,261
Value of shares represented by ASA	\$2.287m
Total number attending meeting	31
Market capitalisation	\$7.46b
ASA open proxies voted	On a poll. ASA voted in favour of the resolutions (except those mentioned in the VI)

Meeting Statistics

All resolutions were soundly passed, with limited questions.

The Chairman opened the meeting by introducing the Directors and commenting on the Board composition and ongoing renewal with the appointment of Rachel Argaman who stood for election, at the meeting

This was followed by the CEO's review of the 2022 results, including a guidance update for the year ahead, especially their commitment to prudent Capital management.

The Directors standing for re-election spoke of their experience and commitment to the Group.

In response to ASA's question to M/s Argaman about her role as CEO of Opal Healthcare, she advised that her contract would expire in July 23.

The remuneration report although opposed by ASA was strongly supported, although the Chairman did comment on the LTI reverting to 2 hurdles in 2023. Whilst not commenting about our concern of the emphasis on the STI component.

A pleasing aspect was the post meeting, with genuine engagement of directors with attendees

ASA Disclaimer

This document has been prepared by the Australian Shareholders Association Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not constitute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommendations of a particular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- makes any representations, warranties or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or information contained in this document; or*
- shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any statements or information contained in, or omissions from this document; nor for any person's acts or omissions undertaken or made in reliance of any such statements, information or omissions.*

This document may contain forward looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cautioned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obligation to disseminate any updates or revisions to any such statements to reflect changed expectations or circumstances.